A Qualitative Study on CSII in Children and Adolescents Having Type 1 Diabetes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03066284|
Recruitment Status : Unknown
Verified February 2017 by nehad Taha, Dasman Diabetes Institute.
Recruitment status was: Recruiting
First Posted : February 28, 2017
Last Update Posted : February 28, 2017
|Condition or disease|
|Type 1 Diabetes Mellitus|
- To explore the experiences of adolescents and their parents and parents ofi children with type 1 diabetes in Kuwait about the use of Insulin Pump Therapy (IPT) in the context of their quality of life.
- To gain in-depth understanding of the perceptions of adolescents and their parents and parents of children with type 1 diabetes in Kuwait with T1DM about IPT and its use for diabetes management.
Design A qualitative case study methodology will be adopted using semi-structured interviews for data gathering. Interviews will be conducted with a purposive sample including adolescents and their parents and parents of children with type 1 diabetes in Kuwait with T1D, who are on CSII therapy at least 12 months, along with their parents.
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||A Qualitative Study on the Experiences and Expectations of Children and Adolescents Having Type 1 Diabetes Towards Insulin Pump Therapy and Its Effect on Their Quality of Life in Kuwait|
|Actual Study Start Date :||March 14, 2016|
|Estimated Primary Completion Date :||March 13, 2017|
|Estimated Study Completion Date :||March 13, 2019|
- Impact of IPT on QoL of children and adolescents from their perspective and their parents' perspective [ Time Frame: 2 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03066284
|Contact: Nehad A. Taha, MSc.||+965-22242999 ext email@example.com|
|Contact: Zahra N. Rahme, MSc||+965-22242999 ext firstname.lastname@example.org|
|Dasman Diabetes Institute||Recruiting|
|Sharq, Kuwait City, Kuwait, 15462/1180|
|Contact: Nehad A. Taha, MSc. +96522242999 ext 2202 email@example.com|
|Contact: Zahraa N. Rahme, MSc. +96522242999 ext 2207 firstname.lastname@example.org|
|Principal Investigator: Naglaa I. Mesbah, MSc.|
|Principal Investigator:||Nehad A. Taha, MSc.||Dasman Diabetes Institute|
|Principal Investigator:||Naglaa I. Mesbah, MSc.||Dasman Diabetes Institute|
|Principal Investigator:||Zahra N. Rahme, MSc.||Dasman Diabetes Institute|